Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production
STOCKHOLM, Sweden, 16 December 2020 – Lipidor AB (Nasdaq First North:LIPI) announced today that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up to SEK 15 million in the new collaboration. Under the agreement, Aurena Laboratories will establish a production unit to meet the regulatory requirements for the manufacture of Lipidor's pharmaceutical products. This will enable Lipidor to offer potential licensees the opportunity for large-scale commercial production. This is an important step towards a licensing